Prospective observational study of primary angioplasty of the infarct-related artery for acute myocardial infarction

• Published in: Indian heart journal Vol. 51; no. 2; pp. 167 - 172
• Main Authors: Reddy, N K, Raju, P R, Kapoor, S, Rao, M S, Reddy, R P, Sastry, B K, Raju, B S
• Format: Journal Article
• Language: English
• Published: India 01.03.1999
• Subjects: Adult; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal - therapeutic use; Anticoagulants - therapeutic use; Coronary Angiography; Feasibility Studies; Female; Hemodynamics; Humans; Immunoglobulin Fab Fragments - therapeutic use; Male; Middle Aged; Myocardial Infarction - diagnostic imaging; Myocardial Infarction - physiopathology; Myocardial Infarction - therapy; Prospective Studies; Recurrence; Stents; Treatment Outcome
• ISSN: 0019-4832

Primary angioplasty has been shown to reduce rates of in-hospital mortality, recurrent ischaemia and infarction. However, the role of primary stenting and abciximab is presently undergoing evaluation. This study attempted to examine the feasibility, safety and outcomes of primary angioplasty in the treatment of acute myocardial infarction. Data in 100 patients who underwent primary angioplasty for evolving acute myocardial infarction was prospectively analysed to assess the safety and efficacy of various modalities. Twenty patients were in Killip class III and above. Multivessel (2 or more vessels) disease was noted in more than 52 cases. Procedural success was 99 percent; 86 patients received primary stenting, majority of them had Kalam-Raju stent implantation. Adjunct treatment included abciximab infusion in 22 and intra-aortic balloon pump support in 12. Overall mortality rate was six percent with a mortality of 2.2 percent in non-cardiogenic shock patients. Recurrent ischaemic events were noted in five, three of them had successful reperfusion with repeat angioplasty. None of the patients had emergency coronary artery bypass surgery. It is concluded that primary angioplasty is safe and effective with high procedural success. Recurrent ischaemic events are low, possibly due to routine use of stenting and selective use of abciximab.